Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... Three companies from the angelMD network were ... Competition. Out of 700 competition entrants, Chiron Health, Litesprite, ... round. In this round twenty teams are invited to ... mentoring from thought-leaders and medical entrepreneurs from all over ... commitment to the Livestrong vision around the Big C ...
(Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus Group ... regulatory and ethical review services for clinical research, ... Formerly a division of Richmond, VA ... leading biosafety and biosecurity consulting firm in ... addition, WCG,s biosafety division – WCG Biosafety™ – ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that for ... 17 different countries will converge on the Draper ... for an intensive, experiential program focused on entrepreneurship, ... highly selective school, currently running its sixth cohort, ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
... , THE WOODLANDS, Texas, Sept. 9 ... company focused on discovering and developing breakthrough treatments for human disease, announced ... president and chief executive officer, will present at the Morgan Stanley Global ... York on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time. ...
... ... software makes its debut at leading industry conferences. , ... Cambridge, MA (PRWEB) September 9, 2009 -- Akaza Research, the leading ... flagship product, OpenClinica, at two major industry conferences this fall. , , ,Representatives from Akaza ...
... Ontario, Sept. 8 Helix BioPharma Corp. (TSX, FSE: "HBP"; OTCQX: "HXBPF") ... 6,625,000 units at $2.05 per unit. , , ... purchase warrant, with each common share purchase warrant entitling the holder to ... price of $2.87 for up to three years after the closing date ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Akaza Research to Present OpenClinica 3.0 at Upcoming Clinical Research Conferences: SoCRA, SCDM 2Helix BioPharma Closes Private Placement 2Helix BioPharma Closes Private Placement 3
(Date:7/24/2014)... reduce fire hazard in the United States, wildland managers ... shrubs and suppressed trees (ladder fuels). These cuttings ... of low fire danger in order to dispose of ... air pollutants, managers often cover all or part of ... to as agricultural plastic, in order to keep water ...
(Date:7/24/2014)... which life arose have been maintained in our cells today ... Research published today in the Journal of Biological Chemistry ... also in animals still perform ancient reactions thought to have ... billion years ago. , The primordial soup theory suggests that ... of the combination of metals, gases from the atmosphere and ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... and technical publishing business of John Wiley & Sons, Inc. ... Taipei have signed an agreement to closely cooperate and jointly ... The journal will be available online from volume 2011 in ... collections of online resources, used by 10 million people a ...
... Drying of northern wetlands has led to much more severe ... the atmosphere, according to new research led by a University ... Nature Communications , is the first to investigate the effect ... vulnerability of that carbon to burning. "Russia, Indonesia and ...
... by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology ... found that a defect in a gene involved in a ... of invasive bladder cancer. The findings are published in the ... Cell Biology . It is the featured research of the ...
Cached Biology News:Journal of the Chinese Chemical Society expands international reach with Wiley-VCH 2Drying intensifying wildfires, carbon release ninefold, study finds 2Mutation in gene associated with rare eye disease also contributes to bladder cancer growth 2
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: